Contents
Academic literature on the topic 'Hormone parathyroïdienne'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hormone parathyroïdienne.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Hormone parathyroïdienne"
Massy, Ziad A., Tilman B. Drueke, and Marielle Romet. "L’hormone parathyroïdienne, simple hormone ou toxine urémique ?" Néphrologie & Thérapeutique 7, no. 1 (February 2011): H1—H4. http://dx.doi.org/10.1016/s1769-7255(11)70003-7.
Full textRizzoli, R., S. Ferrari, J. Caverzasio, L. Vadas, and JP Bonjour. "Effets d'un analogue de l'hormone parathyroïdienne, la parathyroid hormone-related protein, sur le métabolisme phosphocalcique." Immuno-analyse & Biologie Spécialisée 7, no. 6 (December 1992): 45–51. http://dx.doi.org/10.1016/s0923-2532(05)80186-3.
Full textMetzger, M., P. Houillier, M. Flamant, J. P. Haymann, J. J. Boffa, F. Vrtovsnik, A. Karras, et al. "Relation entre vitamine D et hormone parathyroïdienne dans la maladie rénale chronique : existe-il un seuil critique de vitamine D ?" Néphrologie & Thérapeutique 7, no. 5 (September 2011): 271. http://dx.doi.org/10.1016/j.nephro.2011.07.031.
Full textDissertations / Theses on the topic "Hormone parathyroïdienne"
Buaud, Philippe. "Hormone parathyroïdienne et parodonte." Nantes, 1986. http://www.theses.fr/1986NANT1540.
Full textMerciris, Didier. "Rôle des métalloprotéases matricielles ostéoblastiques et du facteur de transcription Runx2 dans l'action anabolique de la parathormone in vivo." Paris 7, 2007. http://www.theses.fr/2007PA077117.
Full textParathyroid hormone (PTH) and its 1-34 fragment (rh 1-34 PTH) increase bone density and bone mass in rodents, primates and humans when administrated intermittently at low dosage. Rh 1-34 PTH administration to post-menopausal women with severe osteoporosis leads to a decrease in bone loss and a reduction in the number of new vertebral fractures. The cellular and molecular mechanisms underling this effect are not well understood. In our study, we have explored two pathways that could possibly be involved in die anabolic action of PTH : Matrix metalloproteinase (MMPs) and the transcription factor Runx2. Other studies have indeed presented evidence that Runx2 could be a key mediator of the enhancement of collagenase-3 expression induced by PTH. In the first part of the study, we treated adult female mice which over express TIMP-1 in osteoblasts and their wild type littermates with PTH at a dose of 40μg/kg/d during 6 weeks. Our study indicates that inhibition of osteoblastic MMPs that reduces bone resorption in vivo has a positive effect on the anabolic treatment with PTH. We showed that the increase in bone resorption induced by PTH is abolished in transgenic mice but also that bone formation is maintained. In the second part of this study, we treated young female mice which over express the transcription factor Runx2 in osteoblast and their wild type littermate with PTH at a dose of 100μg/kg/d during 6 weeks. Our results showed that increasing the level of expression of the Runx2 transcription factor reduced the osteoblastic response to PTH. Our molecular and cellular analysis moreover demonstrated that Runx2 blunt the anabolic effect of PTH probably through a mechanism affecting osteoblastic differentiation. These two independent studies helped us to decipher the molecular mechanisms involving Runx2 and MMPs in the action of PTH. We suggest that Runx2 action in the PTH anabolism is independent from those involving MMPs
El, Hessni Aboubaker. "Liaison et action de l'hormone parathyroïdienne sur les fibroblastes cutanés de sujets sensibles et résistants à cette hormone : effet des glucocorticoïdes." Paris 11, 1988. http://www.theses.fr/1988PA112351.
Full textCorrèze, Marie-Cécile. "Cellules parathyroïdiennes humaines pathologiques en culture : rôle du calcium, du calcitriol, du phosphate et d'un agoniste partiel du récepteur du calcium (NPS R-467) sur la sécrétion d'hormone parathyroïdienne et la prolifération cellulaire." Paris 11, 2000. http://www.theses.fr/2000PA11T025.
Full textMichaud, Josée. "L’inhibition des cytochromes P450 dans les cas d’insuffisance rénale chronique : rôle de l’hormone parathyroïdienne." Thèse, 2012. http://hdl.handle.net/1866/10228.
Full textDani, Mélina. "Modulation du cytochrome P450 par l’insuffisance rénale chronique dans un modèle murin transgénique." Thèse, 2009. http://hdl.handle.net/1866/3561.
Full textChronic renal failure (CRF) is associated with a decrease in the metabolic clearance of drugs, which is partly due to a reduced expression of cytochrome P450 (CYP450) and phase II enzymes, namely N-acetyltransferase 2 (NAT2). This phenomenon has been shown in the rat. We have previously demonstrated the role of parathyroid hormone (PTH) in CYP450 down-regulation in rats with CRF. However, the study of mechanisms underlying the down-regulation of CYP450 by PTH should be confirmed with the use of knockout mice. The aim of this study was, therefore, to confirm these results in a murine model. Firstly, to validate this experimental model, CRF was produced in C57BL/6 mice using the 3/4 subtotal nephrectomy. Protein and mRNA levels of hepatic CYP450 and Nat2 were then analyzed. The results showed that CRF down-regulates these enzymes, as previously observed in the rat. Finally, PTH-null mice (PTH-/-) and their corresponding wild type (PTH+/+) were nephrectomized in order to analyze protein and mRNA expression of hepatic CYP450. If PTH is responsible for the decrease of CYP450 in the presence of CRF, then PTH-/- mice with CRF should not show any reduction in CYP450 expression compared to controls. The results concerning the PTH-/- mice could not be interpreted because PTH+/+ mice with CRF did not show any significant difference of CYP450 expression when compared to PTH+/+ controls. Thus, additional experiments must be conducted in order to determine the role of PTH in CYP450 down-regulation in CRF mice.
Pellicelli, Martin. "Caractérisation de nouveaux mécanismes transcriptionnels impliqués dans la biologie osseuse." Thèse, 2010. http://hdl.handle.net/1866/8762.
Full textBone development and homeostasis need a large amount of molecular signals to be finely regulated in time and space. These signals lead to the activation or to the inhibition of different transcription factors, which are implicated in the control of osteoblast and chondrocyte proliferation and differentiation. The integrity of these mechanisms is required in order to have a healthy life. Indeed, if one of these mechanisms is dysfunctional, different diseases could develop such as hypophosphatemia, osteoporosis and osteoarthritis (OA). In order to contribute to the comprehension of bone biology, the present thesis describes new mechanisms for the transcriptional regulation of two genes implicated in bone development and regulation: PITX1 (Paired-like Homeodomain Transcription Factor 1) and PHEX (Phosphate-regulating gene with homology to endopeptidase on the X chromosome). The first mechanism described in this thesis relates to the transcriptional regulation of PITX1, a gene that encodes for a member of the homeobox family of transcription factors. PITX1 is required in bone development of inferior members and in the maintenance of the articular cartilage integrity in adults. Thereby, we showed that in articular chondrocytes, the expression of PITX1 is activated after the transcription factor E2F1 was recruited at two response elements in the proximal region of its promoter. Moreover, in articular chondrocytes from OA patients, we observed that the expression of PITX1 is strongly decreased. We proposed that the mechanism responsible for this repression requires the multitask protein Prohibitin (PHB1), which is strongly accumulated in OA chondrocyte nuclei, but not in chondrocyte nuclei from healthy individuals. The second mechanism described in this thesis reports a transcriptional mechanism by which PHEX, the gene that encodes for the peptidase mutated in the syndrome X-Linked Hypophosphatemia (XLH)and characterized by hypophosphatemia and osteomalecia, is repressed. We showed that the treatment of osteoblasts with the Parathyroid hormone-related protein (PTHrP) induced a decrease in PHEX expression. In order to characterize the mechanism responsible for this repression, we performed gene reporter experiments and identified two response elements for the transcription factor E4BP4 in the PHEX promoter. The downregulation of E4BP4 by siRNA led to the validation that this repressor decreased the expression of PHEX in osteoblasts after their treatment with PTHrP. In conclusion, the new transcriptional mechanisms presented in this thesis allow a better understanding of PITX1 and PHEX expression. Moreover, the potential role of PHB1 in the establishment of OA presents many interesting possibilities regarding the treatment and diagnosis of this disease. Finally, the characterization of E4BP4 as a mediator of PHEX repression by the PTHrP suggests that E4BP4 could be implicated in the control of bone mineralization and phosphate levels in the blood.